Novo Nordisk A/S (NYSE: NVO) reported third‑quarter 2026 revenue of DKK 79.20 billion (USD 12.03 billion), up 6% in Danish kroner and 4% at constant exchange rates (CER), as obesity‑drug demand supported growth, and raised its full‑year guidance for adjusted sales and operating profit to between −2% and +2% CER, from −6% to 0%, citing improved expectations for GLP‑1 sales. CEO Mike Doustdar said both US and international operations delivered quarterly sales growth.
Q3 2026 Earnings Snapshot
| Item | Detail |
|---|---|
| Q3 Revenue | DKK 79.20 billion (USD 12.03 billion), +6% DKK / +4% CER |
| Nine‑Month Adjusted Revenue | DKK 227.75 billion (USD 34.59 billion), +2% CER |
| Full‑Year Guidance (Raised) | Adjusted sales and operating‑profit growth of −2% to +2% CER, vs. prior −6% to 0% |
| Growth Driver | Obesity‑drug demand; improved GLP‑1 sales expectations |
| Geographic Performance | Both US and international operations posted quarterly sales growth |
| CEO | Mike Doustdar |
Product Performance – Semaglutide Franchise
- Oral Wegovy (semaglutide): Generated DKK 5.39 billion (USD 819 million) in Q3; nine‑month sales reached DKK 10.87 billion (USD 1.65 billion) – the quarter’s standout growth engine.
- Injectable Wegovy: Sales declined 2% CER to DKK 20.41 billion (USD 3.10 billion).
- Injectable Ozempic (semaglutide): Fell 5% to DKK 29.71 billion (USD 4.51 billion), remaining the company’s largest single product line.
- Ozempic pill / Rybelsus (combined): Declined 10% to DKK 4.94 billion (USD 750 million).
Regional Focus – China
Region China revenue – covering Mainland China, the Hong Kong SAR, and Taiwan – declined 5% CER to DKK 5.03 billion (USD 765 million) in Q3; nine‑month revenue fell 2% to DKK 14.78 billion (USD 2.24 billion).
| Product (China) | Q3 Sales | Change |
|---|---|---|
| Ozempic (injectable) | DKK 1.27 billion (USD 193 million) | −22% |
| Ozempic pill / Rybelsus | DKK 46 million (USD 7 million) | −89% |
| Wegovy (injectable) | DKK 327 million (USD 50 million) | +184% |
| Insulin | DKK 2.93 billion (USD 444 million) | +17% |
- Pricing Pressure: Wegovy’s 184% volume‑driven surge came alongside lower realized prices following Chinese list‑price reductions in late 2025, which Novo highlighted in the report.
- Business Mix: Insulin remained the regional business’s largest contributor, underscoring the still‑early stage of China’s GLP‑1 obesity market for Novo.
Pipeline & Clinical Updates
- Oral Wegovy Global Rollout: Available in eight markets as of the results announcement, with more than 20 markets planned during 2027.
- CagriSema (cagrilintide + semaglutide): Remains under regulatory review in the US and China for weight management; Novo expects a US decision in Q4 2026 and, subject to approval, a launch in early 2027.
- Zenaglutide (formerly amycretin): An oral, single‑molecule GLP‑1/amylin receptor agonist advancing as the anchor of Novo’s next‑generation obesity portfolio. The Phase III AMAZE 9 trial will evaluate weight loss over 76 weeks in approximately 950 people with obesity without diabetes, with results expected in H2 2028.
- Cardiovascular Setbacks: Anti‑IL‑6 antibody ziltivekimab failed to reduce major cardiovascular events in ZEUS; a monitoring committee subsequently recommended terminating the HERMES and ATHENA heart‑failure studies.
- Impairments: Novo wrote down the balance‑sheet value of ziltivekimab by DKK 4.6 billion (USD 699 million) and manufacturing assets by DKK 4.1 billion (USD 623 million) as it adjusted its production network.
Market Impact & Outlook
- Guidance Reset: Raising full‑year adjusted sales and operating‑profit growth to −2% to +2% CER signals management confidence that oral Wegovy momentum can offset injectable franchise erosion through year‑end.
- Portfolio Transition: The mix shift – oral Wegovy scaling while injectable Wegovy (−2% CER) and Ozempic (−5%) decline – marks a pivotal formulation transition within the semaglutide franchise.
- China Strategy: With Ozempic down 22% and Rybelsus down 89% locally amid price cuts and intensifying domestic competition, Novo is leaning on Wegovy volume growth, insulin strength, and CagriSema’s pending China review to stabilize the region.
- Pipeline Risk Repricing: The ziltivekimab failure and DKK 8.7 billion in combined writedowns remove a cardiovascular diversification pillar, concentrating near‑term value creation on the obesity portfolio: CagriSema, oral Wegovy, and zenaglutide.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Novo Nordisk’s guidance, regulatory timelines (including the CagriSema US and China reviews), clinical trial outcomes (including AMAZE 9), market launches, and commercial expectations. Actual results may differ materially due to risks including regulatory decisions, pricing and reimbursement pressures, competitive dynamics, clinical setbacks, and foreign‑exchange movements.-Fineline Info & Tech
